{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 39,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a four-column structure to explain the target, the molecule type, preclinical results, and clinical results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/18",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Inhibition of the key cytokines IL-2, IL-9 and IL-15 by EQ101 translates from preclinical models into humans",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39faa36f-ba99-4795-824b-9c73417295af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.03,
        "y": 0.53
      },
      "kind": "list",
      "text": "IL-2 & IL-15 are important to CD8 and NK cell biology, IL-9 contributes to inflammation in the skin. Important to inhibit both IL-2 and IL-15 due to redundancy in signaling on cytotoxic CD8 T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "075b5eab-7dba-43c5-b5e9-8df253cce641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.75,
        "y": 0.53
      },
      "kind": "list",
      "text": "Significant clinical experience in >100 subjects, demonstrated favorable safety and tolerability. Positive proof-of-concept achieved in cutaneous T cell lymphoma patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c36b22f-d4a6-424b-b686-af5d1ad84b8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.51,
        "y": 0.53
      },
      "kind": "list",
      "text": "As effective as ruxolitinib in inhibiting multiple lymphoproliferative or leukemic T-cell lines. More effective than ruxolitinib in mouse model of immune-mediated hair loss / alopecia areata",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "269a6137-26c9-4fb1-aae6-167cd47ba942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.27,
        "y": 0.53
      },
      "kind": "list",
      "text": "PEGylated peptide (based on the D-helix) selectively inhibiting IL-2, IL-9 & IL-15 signaling. Administered as a low volume intravenous push, with a sub-cutaneous formulation in development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7c903c7-ef45-468a-9be8-a678df2c6c4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Nata et al., J. Biol. Chem., 2015; 2) Massoud et al., PNAS, 2015; 3) Wang et al., Leukemia, 2018; 4) Azimi et al., AHRS, Orlando, Florida, 2018 5) Frohna et al., J. Clin. Pharm., 2019 6) Querfeld et al., Blood, 2019",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc65270d-d4de-4508-adca-272cf8bbdc17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: A First-in-Class Tri-Specific Cytokine Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8755caee-147e-41a9-96b2-74d7a377ad1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b4cf2ba5-c98f-40f2-a488-9170cbc4d209",
      "evidence": "The slide contains a list/bullet with several items.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 17,
      "beatId": "1b331d6c-cf93-440f-9b58-a2062c2128d5",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents market sizing information for EQ101",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}